Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUP-R: TDM of Sunitinib and Pazopanib in Advanced or Metastatic RCC
NCT02555748Phase 4Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Nov 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sunitinib, pazopanib in renal cell carcinoma (RCC), sponsored by Institut Claudius Regaud. Started Nov 2015; status: completed.
02
Drugs
sunitinibpazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02555748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555748.